Malaga

• A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i … Ended recruitment
  2023-507236-20-00 9 2020-07-28 Follicular Lymphoma (FL)
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518318-25-00 5 2020-06-24 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended recruitment
  2024-512704-20-00 4 2020-06-22 Unresectable and/or metastatic soft-tissue sarcoma after failure of at
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• Extension of a clinical trial to assess the safety of a study drug called "CORT125134" in the treatment of Cushing Syndrome Ended recruitment
  2024-514079-17-00 10 2020-05-28 Endogenous Cushing Syndrome
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Ended recruitment
  2024-511317-38-00 4 2020-05-04 ALK+ non-small cell lung cancer
• Phase 1/2 Study of CLN-081 in Patients with Lung Cancer Ended recruitment
  2024-516532-97-00 9 2020-03-26 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9) Ended recruitment
  2023-507060-39-00 3 2020-03-04 Multiple Myeloma
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• Research study to look at how well the drug Concizumab works in your body if you have haemophilia without inhibitors Ended recruitment
  2023-506831-13-00 5 2020-01-15 haemophilia A (HA) without inhibitors and haemophilia B (HB) without i
• Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201 Ended recruitment
  2023-508830-33-00 4 2019-12-13 Patients diagnosed with advanced or metastatic cancer treated with Tra
• Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cance … Ended recruitment
  2024-517705-93-00 9 2019-12-13 Histologically or cytologically confirmed diagnosis of extensive or li
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors Ended recruitment
  2023-506832-33-00 5 2019-11-06 haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended recruitment
  2024-510776-20-00 5 2019-10-25 Female or male patients with histologically confirmed HR-positive, HER
• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended recruitment
  2023-508526-10-00 7 2019-10-01 Malignant solid tumors: Patients with relapsed or refractory, advanced
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel … Ended recruitment
  2023-505219-19-00 9 2019-09-03 Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l … Ended recruitment
  2022-502616-37-00 9 2019-07-30 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
• A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended recruitment
  2023-506153-38-00 5 2019-07-11 High-risk localized or locally advanced prostate cancer
• A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after i … Ended recruitment
  2024-512564-58-00 4 2019-07-05 EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Ca

Showing 745–768 of 1,048 trials